Unknown

Dataset Information

0

Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.


ABSTRACT: Natural killer (NK) cells play a pivotal role in monoclonal antibody-mediated immunotherapy through the antibody-dependent cell-mediated cytotoxicity (ADCC) mechanism. NK-92MI is an interleukin-2 (IL-2)-independent cell line, which was derived from NK-92 cells with superior cytotoxicity toward a wide range of tumor cells in vitro and in vivo. Nonetheless, the Fc-receptor (CD16) that usually mediates ADCC is absent in NK-92 and NK-92MI cells. To apply NK-92MI cell-based immunotherapy to cancer treatment, we designed and generated two chimeric receptors in NK-92MI cells that can bind the Fc portion of human immunoglobulins. The construct includes the low-affinity Fc receptor CD16 (158F) or the high-affinity Fc receptor CD64, with the addition of the CD8a extracellular domain, CD28 transmembrane domains, two costimulatory domains (CD28 and 4-1BB), and the signaling domain from CD3ζ. The resulting chimeric receptors, termed CD16-BB-ζ and CD64-BB-ζ, were used to generate modified NK-92MI cells expressing the chimeric receptor, which were named NK-92MIhCD16 and NK-92MIhCD64 cells, respectively. We found that NK-92MIhCD16 and NK-92MIhCD64 cells significantly improved cytotoxicity against CD20-positive non-Hodgkin's lymphoma cells in the presence of rituximab. These results suggest that the chimeric receptor-expressing NK-92MI cells may enhance the clinical responses to currently available anticancer monoclonal antibodies.

SUBMITTER: Chen Y 

PROVIDER: S-EPMC5514896 | BioStudies | 2017-01-01

SECONDARY ACCESSION(S): NM_001127593

REPOSITORIES: biostudies

Similar Datasets

2016-01-01 | S-EPMC5061331 | BioStudies
2013-01-01 | S-EPMC3570461 | BioStudies
1000-01-01 | S-EPMC3461929 | BioStudies
1000-01-01 | S-EPMC5037471 | BioStudies
2013-01-01 | S-EPMC3745217 | BioStudies
2019-01-01 | S-EPMC6774869 | BioStudies
1000-01-01 | S-EPMC5599094 | BioStudies
2020-01-01 | S-EPMC7218403 | BioStudies
2017-01-01 | S-EPMC5384385 | BioStudies
2020-01-01 | S-EPMC7445348 | BioStudies